INDIA MARKET LENS
IPO◆ MixedCorporate ActionsIPO & Listings

Bonus share: Just single issue with record date this week: Pharma firm's free shares with 68% returns since IPO; ratio

Concord Biotech moved lower in a corporate actions development with November 4 in focus.

· LiveMint Markets

Concord Biotech has set November 4 as the record date for its 1:1 bonus issue. Investors must hold shares by November 3 to qualify. The stock closed 1.25% higher at ₹1,245.30 on October 30, though it has fallen about 14.28% over the past year.

Dates in focus
November 4, November 3 and October 30

Concord Biotech reported ₹1,245.30, with movement of 68%, 1.25% and 14.28% attached to those lines. Those are the figures as filed — what moves the price is how they sit against what the market already expected, not their absolute size.

Against that, the stock is +1.2% on the day at ₹1,245.60, and has returned -6.3% over three months. It sits 22% below its 52-week high. The pharma & healthcare sector has moved -0.9% over the same period, so Concord Biotech is running 5.4 points behind its peers.

For Concord Biotech, the question is how much of this is already reflected in the price and how much re-rates the pharma & healthcare peer set alongside it.

  • Buybacks, dividends and splits change what a shareholder actually receives, and often signal how management reads its own value.
  • Listing activity is a read on risk appetite — a hot primary market usually means a confident secondary one.
  • In focus: Concord Biotech (CONCORDBIO), in Pharma & Healthcare.
  • Over three months: Concord Biotech -6.3% against Pharma & Healthcare -0.9% (5.4 points behind).
Figures for the companies in this story
CompanyPriceDay1M3MFrom 52-wk highVolume vs 20-dayMarket cap
Concord BiotechCONCORDBIO · Pharma & Healthcare₹1,245.60+1.2%-9.3%-6.3%-21.5%1.0×—

Pharma & Healthcare

1M -0.6% · 3M -0.9%

Concord Biotech

Prices as of 30 Oct 2026, 16:10 IST. Sector moves are the average of the stocks we track in each sector.

CONCORDBIOPharma & Healthcare